Comprehensive Pharmacovigilance Analysis of Lebrikizumab: A Real-World Safety Assessment Based on the FDA Adverse Event Reporting System (FAERS) Database
This study provides a comprehensive overview of the safety of lebrikizumab and confirms that it has a favorable and manageable safety profile, supporting its suitability for long-term use in clinical practice.
Authors
- Chengjie Ke (ORCID: https://orcid.org/0009-0007-9421-6951)
- Maohua Chen (ORCID: https://orcid.org/0000-0001-7393-4523)
- Yaping Huang
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Comprehensive Clinical Research (US)
Publication Details
- Journal
- Immunopharmacology and Immunotoxicology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1080/08923973.2026.2648209
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00